Vertex Pharmaceuticals (VRTX) Q2 2025 10-Q Quarterly Report
Vertex Pharmaceuticals (VRTX) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 5, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Vertex Pharmaceuticals Q2 2025 10-Q Analysis
Risk Factors
- • No new or materially changed risk factors disclosed in quarterly filing versus most recent 10-K
- • Regulatory risk: ongoing FDA interactions and accelerated approvals remain critical for clinical trial timelines and product launches
Vertex Pharmaceuticals Q2 2025 Quarterly FinancialsXBRL
Revenue
$3.0B
▲ +12.1% YoY▲ +7.0% QoQ
Net Income
$1.0B
▲ +128.7% YoY▲ +59.8% QoQ
Net Margin
34.8%
▲ +17067bp YoY▲ +1151bp QoQ
Source: XBRL data from Vertex Pharmaceuticals Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Vertex Pharmaceuticals Quarterly Reports
Get deeper insights on Vertex Pharmaceuticals
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.